The Business Brew Peter Mantas Returns
Oct 15, 2025
Peter Mantas, co-founder of Logos LP and expert in life sciences investing, shares insights on the recent developments in biotech. He discusses uniQure's promising Huntington's data and its implications for treatment. Mantas explains macro drivers behind the biotech rally and highlights key companies like Twist Bioscience for their DNA-synthesis technology. He emphasizes the importance of cautious investment in de-risked biotechs and assesses the sustainability of the current biotech rally, urging listeners to be mindful of potential volatility.
AI Snips
Chapters
Transcript
Episode notes
ClearPoint's Long Slog To A Parabolic Move
- ClearPoint was a long pain trade: it traded around $4.70 in Oct 2023 and later touched $30 after catalysts.
- Peter describes the investor chat as durable and fanatical through long drawdowns and explosive up-days.
Tools Business Is Razor + Blade Recurring Demand
- ClearPoint is a medtech tool company selling neurosurgery equipment and single-use cannulas tied to cell and gene therapy delivery.
- Its business combines capital equipment 'razor' installs with recurring consumable 'razor-blade' cannula demand, linking growth to approved therapies.
Huntington's Readout Drove Demand For Delivery Tools
- uniQure's Phase III readout materially slowed Huntington's progression and spurred ClearPoint demand because ClearPoint enables delivery.
- The therapy appears safe and localized, reducing systemic toxicity compared with systemic gene approaches.